A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors
← catalyst calendarSponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
67actual
Sites
19
Countries
Argentina, Belgium, Canada +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2021-08-09 | actual | When the study began enrolling |
| Primary completion | 2025-02-27 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-02-27 | actual | The whole study's end, after follow-up |
| First posted | 2021-06-29 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-09 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Advanced Solid Tumors
Interventions
- Drug: BMS-986416
- Drug: Nivolumab — also filed as BMS-936558, Opdivo
Primary outcomes
what the primary-completion date above is the date OFIncidence of Adverse Events (AEs)
measured Up to 100 days after the last treatment of study intervention(s)
Incidence of Serious Adverse Events (SAEs)
measured Up to 100 days after the last treatment of study intervention(s)
Incidence of AEs meeting protocol-defined dose-limiting toxicity (DLT) criteria
measured Up to 100 days after the last treatment of study intervention(s)
Incidence of AEs leading to discontinuation
measured Up to 100 days after the last treatment of study intervention(s)
Incidence of AEs leading to death
measured Up to 100 days after the last treatment of study intervention(s)
Protocol-defined maximum tolerated dose (MTD) or maximum administered dose (MAAD)
measured Up to 100 days after the last treatment of study intervention(s)
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed